


### Amendments to the Claims

The following listing of claims replaces all prior listings and version of claims in this application.

1. (Currently Amended) A compound of Formula I:



Formula I

wherein:

R<sub>1</sub> and R<sub>2</sub> are independently selected from the group consisting of hydrogen, a lower alkyl group, a lower alkoxy group, substituted or unsubstituted phenyl group, a lower alkyl substituted with at least one substituent selected from the group consisting of a phenyl group, a halogen, hydroxyl, thiol, nitro, cyano, or amino group; m and n are each independently 0-3;

X is selected from the group consisting of SO<sub>2</sub>-NH, S and O ;

M represents substituted or unsubstituted alkylene of 1-4 carbon atoms;

Y is selected from the group consisting of amide, amine, urea, carbamate, hydrazine or sulfonamide;

~~W is absent or is selected from the group consisting of substituted or unsubstituted alkylene, aliphatic, aromatic or heterocyclic moiety, of 1-18 carbon atoms;~~

~~L is absent or is selected from the group consisting of amide, amine, urea, carbamate, hydrazine or sulfonamide; and~~

~~Z is a peptide or peptidomimetic moiety of 4-12 residues in length capable of binding to the substrate site of PKB Arg—Pro—Arg—R<sub>4</sub>—R<sub>5</sub>—R<sub>6</sub>—R<sub>7</sub>;~~

R<sub>4</sub>, R<sub>5</sub>, and R<sub>6</sub> are each independently selected from the group consisting of threonine, serine, glutamic acid allyl ester, homocitrulline, lysine, methionine, norleucine, ornithine, arginine, glycine, diaminopropionic acid, diaminobutyric acid, GlyNH<sub>2</sub>, and alanine; or are an

N<sup>α</sup>-ω-functionalized derivative of an amino acid selected from the group of glycine, alanine and tyrosine;

R<sub>7</sub> is selected from the group consisting of phenylalanine, homoleucine, norleucine, glutamic acid allyl ester;

W may be absent so that Y is connected to L or R<sub>4</sub>, or W is N-(8-sulfonamide-5-isoquinoline) ethylenediamine; and

L may be absent so that W (if present) or Y is connected to R<sub>4</sub>, or L is selected from the group consisting of glycine, β-alanine, phenylalanine, aminobutyric acid and aminopentanoic acid and connects W (if present) or Y with R<sub>4</sub>.

2. (Currently Amended) The compound of claim 1 wherein, in Formula I:

R<sub>1</sub> and R<sub>2</sub> are independently selected from the group consisting of methyl, ethyl, ethoxy and dimethylamine;

m and n are each 1;

~~X is selected from the group consisting of SO<sub>2</sub>-NH and S;~~

M represents substituted or unsubstituted alkylene of 2 carbon atoms; and

Y is selected from the group consisting of amide and amine;

~~W is absent or is selected from the group consisting of substituted or unsubstituted alkylene, aliphatic, aromatic or heterocyclic moiety of 1-5 carbon atoms;~~

~~L is absent or is selected from the group consisting of amide and amine; and~~

~~Z is a peptide or peptidomimetic moiety of 6-10 residues in length capable of binding to the substrate site of PKB.~~

Claims 3. to 6. (Cancelled)


7. (Original) The compound according to claim 1 comprising the sequence:  
Arg-Pro-Arg-Thr-Glu- (bAla-5-mercaptoaminopropyl-isoquinoline)-Ser-Phe.

8. (Original) The compound according to claim 1 comprising the sequence:  
Arg-Pro-Arg-Thr-Glu- (5-mercaptoaminopropyl-isoquinoline)-Ser-Phe.

9. (Original) The compound according to claim 1 comprising the sequence:  
Arg-Pro-Arg-Om-Glu- (5-aminoethylsulfonamide isoquinoline)-Ser-Phe.
10. (Original) The compound according to claim 1 comprising the sequence:  
Arg-Pro-Arg-Nva-Glu- (5-mercaptoaminopropyl-isoquinoline)-Ser-Phe.
11. (Original) The compound according to claim 1 comprising the sequence:  
Arg-Pro-Arg-Nle-Glu- (5-mercaptoaminopropyl-isoquinoline)-Ser-Phe.
12. (Original) The compound according to claim 1 comprising the sequence:  
Arg-Pro-Arg-Orn-Glu-(Gly-5-aminoethylsulfonamide)-Dab-Hol.
13. (Original) The compound according claim 1 comprising the sequence:  
Arg-Pro-Arg-Nle-Glu- (Gly-5-aminoethylsulfonamide)-Dab-Phe.
14. (Original) The compound according to claim 1 comprising the sequence:  
Arg-Pro-Arg-Nle-Glu-(Gly-5-aminoethylsulfonamide)-Dab-Hol.
15. (Original) A pharmaceutical composition comprising as an active ingredient a compound according to claim 1, and a pharmaceutically acceptable diluent or carrier.
16. (Original) A protein kinase inhibitor comprising as an active ingredient a compound according to claim 1, and a pharmaceutically acceptable diluent or carrier.
17. (Original) A method of treatment of a disease comprising administering to a patient in need thereof a therapeutically effective amount of a compound according to claim 1.
18. (Original) The method according to claim 17 wherein the disease is selected from the group comprising cancers, diabetes, cardiovascular pathologies, hemorrhagic shock, obesity, inflammatory diseases, diseases of the central nervous system, and autoimmune diseases.

19. (Original) A method of diagnosis of a disease comprising administering to a patient in need thereof a diagnostically effective amount of a compound according to claim 1.

20. (New) A compound of Formula I:



Formula I

wherein:

$R_1$  and  $R_2$  are independently selected from the group consisting of hydrogen, a lower alkyl group, a lower alkoxy group, substituted or unsubstituted phenyl group, a lower alkyl substituted with at least one substituent selected from the group consisting of a phenyl group, a halogen, hydroxyl, thiol, nitro, cyano, or amino group; m and n are each independently 0-3;

X is selected from the group consisting of  $SO_2-NH$ , S and O ;

M represents substituted or unsubstituted alkylene of 1-4 carbon atoms;

Y is selected from the group consisting of amide, amine, urea, carbamate, hydrazine or sulfonamide;

W is absent or is selected from the group consisting of substituted or unsubstituted alkylene, aliphatic, aromatic or heterocyclic moiety, of 1-18 carbon atoms;

L is absent or is selected from the group consisting of amide, amine, urea, carbamate, hydrazine or sulfonamide; and

Z is a peptide or peptidomimetic moiety comprising one of the following sequences:  
sequence:

Arg-Pro-Arg-Thr-Glu- (bAla-5-mercaptoaminopropyl-isoquinoline)-Ser-Phe;

Arg-Pro-Arg-Thr-Glu- (5-mercaptoaminopropyl-isoquinoline)-Ser-Phe;

Arg-Pro-Arg-Om-Glu- (5-aminoethylsulfonamide isoquinoline)-Ser-Phe;

Arg-Pro-Arg-Nva-Glu- (5-mercaptoaminopropyl-isoquinoline)-Ser-Phe;

Arg-Pro-Arg-Nle-Glu- (5-mercaptoaminopropyl-isoquinoline)-Ser-Phe;

Arg-Pro-Arg-Orn-Glu-(Gly-5-aminoethylsulfonamide)-Dab-Hol;  
Arg-Pro-Arg-Nle-Glu- (Gly-5-aminoethylsulfonamide)-Dab-Phe; or  
Arg-Pro-Arg-Nle-Glu-(Gly-5-aminoethylsulfonamide)-Dab-Hol.

21. (New) A pharmaceutical composition comprising as an active ingredient a compound according to claim 20, and a pharmaceutically acceptable diluent or carrier.

22. (New) A protein kinase inhibitor comprising as an active ingredient a compound according to claim 20, and a pharmaceutically acceptable diluent or carrier.

23. (New) A method of treatment of a disease comprising administering to a patient in need thereof a therapeutically effective amount of a compound according to claim 20.

24. (New) The method according to claim 23 wherein the disease is selected from the group comprising cancers, diabetes, cardiovascular pathologies, hemorrhagic shock, obesity, inflammatory diseases, diseases of the central nervous system, and autoimmune diseases.